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Objectives This study sought to assess whether the frequency of inducible myocardial ischemia during stress-rest single-
photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) has changed over time.
Background The prevalence of cardiac death and other clinical cardiac events have declined in recent decades, but hereto-
fore no study has examined if there has been a temporal change in the frequency of inducible myocardial
ischemia during cardiac stress testing.
Methods We assessed 39,515 diagnostic patients undergoing stress-rest MPI between 1991 and 2009. Patients were assessed
for change in demographics, clinical symptoms, risk factors, and frequency of abnormal and ischemic SPECT-MPI.
Results There was a marked progressive decline in the prevalence of abnormal SPECT studies, from 40.9% in 1991 to
8.7% in 2009 (p  0.001). Similarly, the prevalence of ischemic SPECT-MPI declined, from 29.6% to 5.0%
(p  0.001), as did the prevalence of severe ischemia. The decline of SPECT-MPI abnormality occurred among
all age and symptom subgroups, falling to only 2.9% among recent exercising patients without typical angina.
We also noted a progressive trend toward performing more pharmacological rather than exercise stress in all
age and weight groups, and pharmacological stress was more likely than exercise to be associated with SPECT-
MPI abnormality (odds ratio: 1.43, 95% confidence interval: 1.3 to 1.5; p  0.001).
Conclusions Over the past 2 decades, the frequency and severity of abnormal stress SPECT-MPI studies has progressively de-
creased. Notably, the frequency of abnormal SPECT-MPI is now very low among exercising patients without typical
angina. These findings suggest the need for developing more cost-effective strategies for the initial work-up of pa-
tients who are presently at low risk for manifesting inducible myocardial ischemia during cardiac imaging
procedures. (J Am Coll Cardiol 2013;61:1054–65) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.056p
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dCardiac stress tests are widely used for the diagnostic
workup of patients with suspected coronary artery disease
(CAD). This use is predicated on their ability to signal the
presence of hemodynamically significant CAD through the
induction of myocardial ischemia during cardiac stress
testing. Since the advent of cardiac stress imaging proce-
dures in the 1970s, there has been a progressive decline in
the prevalence of cardiac death (1,2), myocardial infarction
From the *Division of Cardiology and Department of Medicine, St. Luke’s Roosevelt
Hospital, New York, New York; †Department of Imaging, Burns and Allen Research
Institute, Cedars-Sinai Medical Center, Los Angeles, California; and the ‡Depart-
ment of Medicine, Burns and Allen Research Institute, Cedars-Sinai Medical Center,
Los Angeles, California. Dr. Berman has reported having relationships with
Lantheus Medical Imaging, Astellas Pharma US, Inc., GE Healthcare, Siemens,
Cardium Therapeutics, Spectrum Dynamics, and Cedars-Sinai. All other authors
have reported that they have no relationships relevant to the contents of this paper to
disclose.
Manuscript received July 3, 2012; revised manuscript received November 10, 2012,
accepted November 12, 2012.(3–5), stroke (6), and claudication (7). Furthermore, the
revalence of various CAD risk factors has changed dra-
atically within society (1,8–10). Nevertheless, heretofore,
o study has examined if, and to what extent, the frequency
f inducible myocardial ischemia has changed in conjunc-
ion with these temporal trends. Accordingly, in this study,
e assessed the frequency of test abnormality and inducible
yocardial ischemia over the last 2 decades among a large,
onsecutive cohort of patients undergoing stress-rest single-
hoton emission computed tomography (SPECT) myocar-
ial perfusion imaging (MPI).
See page 1066
Methods
Study design. Our study population consisted of 51,689
consecutive patients who were part of an ongoing prospec-
tive registry of SPECT-MPI patients at Cedars-Sinai Med-
ical Center between January 1991 and December 2009.
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March 12, 2013:1054–65 Temporal Trends in IschemiaFrom this pool, we excluded 12,174 patients with prior
myocardial infarction, percutaneous coronary intervention
and/or coronary bypass surgery, or with a history of cardio-
myopathy or valvular heart disease. The remaining 39,515
patients constituted our sample and were divided into 4
successive temporal subgroups: 1991 to 1995; 1996 to 2000;
2001 to 2005; and 2006 to 2009. For patients undergoing
more than 1 SPECT-MPI study, only the earliest SPECT-
MPI study was considered. The study was approved by the
Cedars-Sinai Medical Center Institutional Review Board.
Data collection. At the time of testing, patients completed a
questionnaire regarding pertinent demographic information,
chest pain symptoms, cardiac risk factors, and medication use.
Additionally, resting heart rate, blood pressure, height, and
weight were recorded. We used the responses from 3 questions
regarding patients’ chest pain (its location, precipitants, and
relief with rest or nitroglycerin) to classify each patient into 1 of
4 chest pain categories: asymptomatic, nonanginal chest pain,
atypical angina, and typical angina (11). Asymptomatic pa-
ients complaining of dyspnea were considered separately (12).
family history of premature CAD was considered present if
primary relative had diagnosed CAD or cardiac event at55
ears of age; current smoking was defined as either currently
moking cigarettes or having stopped smoking for 1 year.
ypertension, hypercholesterolemia, and diabetes were de-
ned on the basis of history and/or taking antihypertensive,
ipid-lowering, or diabetic medications, respectively. A Bayes-
an pre-test likelihood of CAD was calculated for each patient
ased on age, sex, risk factors, and chest pain symptoms using
validated commercial program (13). Information regarding
aseline medications was not recorded before 1999.
Patients either underwent treadmill exercise (55.2%, n 
1,830) or pharmacological stress using either adenosine or
ipyridamole (42.4%, n  16,735) or dobutamine infusion
2.4%, n  950). Exercise testing was performed using the
ymptom-limited Bruce protocol. Patients who began exer-
ise but who could not achieve 85% of their maximal
redicted heart rate were generally converted into adenosine
r dobutamine studies. Heart rate, blood pressure, and
lectrocardiographic tracings were obtained at rest, at the
nd of each stress stage, peak stress, and for each of 5-min
fter stress. Dual isotope SPECT-MPI imaging was per-
ormed, using thallium Tl 201 (3 to 4.5 mCi) for rest
PECT-MPI and technetium Tc 99m sestamibi (25 to 40
Ci) for stress SPECT-MPI studies (14). In June 2007, the
rotocol was changed to same-day rest/stress sestamibi
PECT-MPI (rest dose: 7 to 9 mCi, stress dose: 32 to 40
Ci). Resting thallium Tl 201 SPECT-MPI was initiated
0 min after resting radionuclide injection. For exercise and
obutamine studies, the radioisotope was injected at near
aximal stress and SPECT-MPI was begun 15 to 30 min
fter testing. For adenosine testing, technetium Tc 99m sesta-
ibi was injected at the end of the second minute or at the end of
he third minute of 5-min or 6-min adenosine infusions, respec-
ively (140 g/kg/min for both) (15). In 1996, our adenosineprotocol was modified to include an “adeno-walk” protocol,involving concomitant low-level
treadmill exercise. In the patients
not undergoing the adeno-walk,
SPECT imaging was delayed to
60 min after adenosine infusion.
Beginning in 1995, routine 8-/16-
frame gated MPI was also incorpo-
rated into our post-stress acquisition
protocol (16).
Throughout, patients were in-
structed to withhold beta-blocking
medication for 48 h and calcium
blockers for 24 h prior to testing, but 5.0% of patients were
tested under the influence of beta-blocking medication and
3.8% were tested under the influence of calcium-blocking
medications.
SPECT-MPI was performed using multidetector scintil-
lation cameras according to elliptical 180° acquisition of 60
to 64 projections, with 20-s acquisition time per projection.
For thallium Tl 201, 2 energy windows were used: a 30%
window centered on the 68- to 80-keV peak; and a 10%
window centered on the 167 keV peak. For technetium Tc
99m sestamibi, a 15% window centered on the 140-keV
peak was used. Between 1991 and 1993, images were
obtained in the supine position; in 1994 to 1995, additional
prone images were obtained if needed after viewing the
supine images; and after 1995, images were routinely
obtained in both the supine and prone positions (17). No
attenuation correction was applied to our images.
SPECT-MPI interpretation. Semiquantitative visual in-
terpretation was performed by experienced observers using a
5-point score (0  normal to 4  absence of detectable
tracer uptake) for each of either 20 myocardial segments
before February 2005 or 17 segments after February
2005, and summed stress, rest, and difference scores were
then generated. These indices were converted to percent-
ages of abnormal and ischemic myocardium by dividing
the summed scores by 80, the maximal potential score for
20-segment analysis, and by 68 for 17-segment analysis,
and then multiplying by 100. Normal, mild, moderate,
and severe abnormal and ischemic myocardium were
defined as scores 5%, 5% to 9%, 10% to 14%, and
15%, respectively. SPECT studies were also assessed
visually for the presence of transient ischemic dilation of
the left ventricle.
Follow-up. Follow-up for all-cause mortality was con-
ducted using the social security death index. The last date of
access was May 20, 2011. The mean follow-up was for 9.3 
4.7 years (median: 9.0 years; range 0.01 to 20.4 years), with
the patients in the earliest epoch followed for the longest
duration (15.4  3.9 years) and the patients in the last
epoch followed for the shortest duration (3.5  1.1 years).
We then compared annualized mortality rates among the 4
temporal groups. Follow-up data was available in 36,727
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CAD  coronary artery
disease
MPI  myocardial perfusion
imaging
SPECT  single-photon
emission computed
tomography(92.9%) of our patients.
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Temporal Trends in Ischemia March 12, 2013:1054–65Statistical analyses. Stata software (version 11.2, Stata-
Corp., College Station, Texas) was used to analyze the data.
Continuous variables were compared across four groups
using the Kruskal-Wallis test, and for ordered groups,
Cuzick test for trend was added. Categorical variables were
compared using Pearson chi-square test, and the chi-square
test for trend added for ordered groups as well. Annualized
mortality rates were calculated by dividing the number of
events by person-years and were compared using the log-
Comparison of Clinical Characteristics Among the Temporal PatienTable 1 Comparison of Clinical Characteristics A ong the Tem
Parameters
1991–1995
(n  6,335)
1996–2
(n  10
Age, yrs 64.1 12.6 63.9
55 1,534 (24.2) 2,698 (
55–64 1,408 (22.2) 2,288 (
65 3,393 (53.6) 5,278 (
Sex
Male 3,487 (55.0) 5,502 (
Female 2,848 (45.0) 4,762 (
Ethnicity
Caucasian 5,015 (79.2) 7,431 (
African American 506 (8.0) 991 (
Asian/Pacific Islander 213 (3.4) 325 (
Hispanic/Latino 123 (1.9) 384 (
Other/Unknown 478 (7.6) 1,133 (
Patient status
Outpatient 4,558 (72.0) 7,371 (
Inpatient 1,777 (28.1) 2,890 (
Emergency department — —
Chest pain symptoms
Asymptomatic 2,028 (32.0) 2,799 (
Nonanginal chest pain 1,642 (25.9) 1,706 (
Atypical angina 1,569 (24.8) 3,632 (
Typical angina 803 (12.7) 1,126 (
Dyspnea only 292 (4.6) 1,001 (
Coronary disease risk factors
Family history 1,433 (22.6) 2,398 (
Hypertension 2,953 (46.6) 5,313 (
High cholesterol 2,570 (40.6) 4,606 (
Smoking 1,055 (16.7) 1,208 (
Diabetes 871 (13.8) 1,102 (
Weight 165.7 35.3 171.1
Body mass index, kg/m2 26.3 4.7 27.2
Normal, 25 2,676 (42.7) 3,786 (
Overweight, 25–29.9 2,481 (39.5) 4,068 (
Obese, 30 1,117 (17.8) 2,364 (
Resting hemodynamics
Heart rate, beats/min 70.0 13.0 71.8
Systolic blood pressure, mm Hg 143.9 24.8 141.7
Diastolic blood pressure, mm Hg 83.6 11.4 81.6
Rest electrocardiogram
Abnormal rest electrocardiogram 4,114 (64.9) 5,644 (
Left ventricular hypertrophy 736 (11.6) 1,194 (
Left bundle branch block 173 (2.7) 261 (
Atrial fibrillation 151 (2.4) 259 (rank test and test for trend for ordered groups.Logistic regression was done to obtain the risk-adjusted
odds ratio of clinical factors predicting abnormal SPECT in
each temporal period.
A propensity matching score was developed to match
1,000 randomly selected patients from the earliest epoch
(1991 to 1995) to 1,000 patients of each of the other 3
epochs based on age, sex, symptom class, stress mode, body
mass index, cholesterol, diabetes, hypertension, smoking,
and family history. The propensity score was generated from
upsl Patient Groups
2001–2005
(n  14,089)
2006–2009
(n  8,827) p Values (Trend)
60.7 13.7 59.1 13.7 0.0001 (0.001)
4,949 (35.1) 3,403 (38.6)
3,526 (25.0) 2,403 (27.2)
5,614 (39.9) 3,021 (34.2) 0.001 (0.0001)
7,257 (51.5) 4,531 (51.3)
6,832 (48.5) 4,296 (48.7) 0.001 (0.0001)
9,336 (66.3) 5,305 (60.1)
2,170 (15.4) 1,767 (20.0)
633 (4.5) 560 (6.3)
1,059 (7.5) 982 (11.1)
891 (6.3) 213 (2.4) 0.001 (0.0001)
8,846 (62.8) 5,029 (57.0)
4,724 (33.5) 3,000 (34.0)
519 (3.7) 798 (9.0) 0.001 (0.0001)
3,207 (22.8) 2,002 (22.7)
1,509 (10.7) 468 (5.3)
7,737 (54.9) 5,260 (59.6)
476 (3.4) 164 (1.9)
1,160 (8.2) 932 (10.6) 0.001 (0.0001)
1,647 (11.7) 1,229 (13.9) 0.001 (0.0001)
8,238 (58.5) 5,549 (62.9) 0.001 (0.0001)
6,397 (45.4) 4,386 (49.7) 0.001 (0.0001)
1,026 (7.3) 747 (8.5) 0.001 (0.0001)
2,190 (15.5) 1,712 (19.4) 0.001 (0.0001)
177.3 46.6 181.1 51.2 0.0001 (0.001)
28.0 6.5 28.6 7.1 0.0001 (0.001)
4,781 (34.0) 2,886 (32.8)
5,270 (37.5) 3,119 (35.4)
3,996 (28.5) 2,807 (31.9) 0.001 (0.0001)
70.5 13.1 69.2 12.8 0.0001 (0.001)
138.9 20.1 139.3 20.4 0.0001 (0.001)
78.0 10.7 78.5 10.8 0.0001 (0.001)
6,342 (45.0) 3,876 (43.9) 0.001 (0.0001)
662 (4.7) 387 (4.4) 0.001 (0.0001)
252 (1.8) 136 (1.5) 0.001 (0.0001)
303 (2.2) 180 (2.0) 0.09 (0.03)
Continued on the next paget Gropora
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March 12, 2013:1054–65 Temporal Trends in Ischemiamodels that predicted being in each of the latter 3 epochs
versus being in the earliest epoch, with the aforementioned
risk factors in the models. Thus, 3 separate propensity
score-matchings were done; that is, every epoch was
matched to the first epoch, separately. The resulting pro-
pensity scores were then used to match every patient from a
latter epoch to a similar patient in the first epoch (1:1) using
Mahalanobis nearest-neighbor matching algorithm (18).
ContinuedTable 1 Continued
Parameters
1991–1995
(n  6,335)
1996–2
(n  10
Pre-test likelihood of CAD
Mean CAD likelihood 40.1 30.2 44.7
Low CAD likelihood, 15% 1,871 (29.5) 2,602
Intermediate likelihood, 15%–84% 3,630 (57.3) 6,035
High CAD likelihood, 85% 833 (13.2) 1,627
Medication use
Lipid-lowering medications — 481/2,553
Statins — 460
Ezetimibe — 0
Other lipid medications — 25
Antihypertensive medications — 631/2,553
Beta-blockers — 333
ACE inhibitors — 181
ARBs — 40
Calcium blockers — 170
Diuretics — 137
Oral diabetic medications — —
Aspirin — 207
Stress test mode
Exercise 4,454 (70.3) 6,014
Pharmacological 1,881 (29.7) 4,250
Use of pharmacological testing by
subgroups of age and BMI
55 yrs 192 (12.5) 601
55–64 yrs 305 (21.7) 708
65 yrs 1,384 (40.8) 2,941
Normal, 25 kg/m2 790 (29.5) 1,578
Overweight, 25–29.9 kg/m2 661 (26.6) 1,528
Obese, 30 kg/m2 403 (36.1) 1,121
SPECT results
Sum stress score 5% 2,046 (32.3) 1,666
Sum difference score 5% 1,620 (25.6) 1,372
Sum stress score 10% 1,233 (19.5) 1,013
Sum difference score 10% 927 (14.6) 775
% with TID of the left ventricle 244 (3.9) 276
Deaths
All patients 2,749 (43.4) 3,067
Exercise patients 1,436 (32.2) 987
Pharmacologic patients 1,313 (69.8) 2,080
Annual mortality rates, %/yr (95% CI)
All patients 3.3 (3.2–3.4) 3.0
Exercise patients 2.2 (2.1–2.3) 1.5
Pharmacologic patients 7.2 (6.8–7.6) 5.9
Values are mean  SD or n (%) unless otherwise indicated. —  data were unavailable. *Data a
ACE  angiotensin converting enzyme; ARB  angiotensin receptor blocker; BMI  body ma
omputed tomography; TID  transient ischemic dilation.This matching resulted in 4,000 patients (1,000 in each pepoch) with similar clinical profiles as patients seen in the
1991 to 1995 epoch.
Results
The clinical characteristics of our patient population are
shown in Table 1. There was a progressive decrease in the
ean age of our patient population, a mild increase in the
2001–2005
(n  14,089)
2006–2009
(n  8,827) p Values (Trend)
46.8 30.3 49.2 30.6 0.0001 (0.001)
3,181 (22.6) 1,871 (21.2)
8,610 (61.1) 5,296 (60.0)
2,298 (16.3) 1,659 (18.8) 0.001 (0.0001)
3,714 (26.4) 3,010 (34.1) 0.001 (0.0001)
3,541 (25.1) 2,726 (30.9) 0.001 (0.0001)
69 (0.5) 380 (4.3) 0.001 (0.0001)
219 (1.6) 437 (5.0) 0.001 (0.0001)
6,466 (45.9) 4,689 (53.1) 0.001 (0.0001)
2,753 (19.5) 2,158 (24.5) 0.001 (0.0001)
2,443 (17.3) 1,619 (18.3) 0.001 (0.0001)
953 (6.8) 1,314 (14.9) 0.001 (0.0001)
1,544 (11.0) 1,178 (13.4) 0.001 (0.0001)
1,907 (13.5) 1,468 (16.6) 0.001 (0.0001)
— 714 (8.1) —
3,502 (24.9) 2,613 (29.6) 0.001 (0.0001)
7,173 (50.9) 4,189 (47.5)
6,916 (49.1) 4,638 (52.5) 0.001 (0.0001)
1,705 (34.5) 1,300 (38.2) 0.001 (0.0001)
1,457 (41.3) 1,216 (50.6) 0.001 (0.0001)
3,754 (66.9) 2,122 (70.2) 0.001 (0.0001)
2,343 (49.0) 1,496 (51.8) 0.001 (0.0001)
2,321 (44.0) 1,453 (46.6) 0.001 (0.0001)
2,236 (56.0) 1,676 (59.7) 0.001 (0.0001)
1,638 (11.6) 829 (9.4) 0.001 (0.0001)
1,328 (9.4) 530 (6.0) 0.001 (0.0001)
822 (5.8) 416 (4.7) 0.001 (0.0001)
600 (4.3) 216 (2.5) 0.001 (0.0001)
330 (2.3) 56 (1.6)* 0.001 (0.008)
2,290 (18.5) 685 (8.7) 0.001 (0.0001)
399 (6.3) 69 (1.8) 0.001 (0.0001)
1,891 (31.2) 616 (15.1) 0.001 (0.0001)
.1) 2.6 (2.5–2.7) 2.6 (2.4–2.8) 0.002 (0.0003)
.6) 0.8 (0.7–0.9) 0.5 (0.4–0.6) 0.001 (0.0001)
.2) 4.8 (4.6–5.0) 4.7 (4.4–5.1) 0.001 (0.0001)
until June 2007.
x; CAD  coronary artery disease; CI  confidence interval(s); SPECT  single-photon emission000
,264)
30.8
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(58.8)
(15.9)
(18.8)
(18.0)
(0)
(1.0)
(24.7)
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Temporal Trends in Ischemia March 12, 2013:1054–65groups, a decrease in the percent of outpatients, and a
decline in both the percentage of asymptomatic and typical
angina patients referred for testing. There was a decrease in
the percentage of patients with a family history of premature
CAD and in those who were current smokers, but an
increase in the percentage who had hypertension, high
cholesterol, diabetes, and obesity. However, mean resting
systolic and diastolic blood pressure measurements were
lower for the 2006 to 2009 cohort versus the 1991 to 1995
cohort. Concomitantly, there was a progressive increase in
the use of aspirin and lipid-lowering and antihypertensive
medications. There was also a temporal decline in the
percentage of patients with an abnormal resting electrocar-
diogram or left ventricular hypertrophy. Overall, the mean
pre-test Bayesian likelihood of CAD rose from 40.1% to
49.2% during the 4 temporal periods, and the majority of
patients tested had an intermediate (15% to 84%) pre-test
likelihood of CAD.
There was also a progressive decline in the frequency of
patients who were tested with exercise as opposed to
pharmacological stress. During the 1991 to 1995 epoch,
70.3% of patients underwent stress SPECT-MPI using
exercise testing but by the 2006 to 2009 epoch, only 47.5%
of the patients underwent exercise testing. The increasing
use of pharmacological testing was noted both among
younger and older patients and among normal weight,
overweight, and obese patients. Annualized all-cause mor-
tality rates declined during each epoch between both pa-
tients undergoing exercise and patients undergoing pharma-
cological stress testing.
Temporal change in the frequency of abnormal and
ischemic SPECT-MPI studies. As shown in Figure 1,
here was a marked progressive temporal decline in the
revalence of abnormal stress SPECT-MPI studies, ranging
rom 40.9% in 1991 to only 8.7% in 2009 (p 0.0001), and
parallel decline in the prevalence of ischemic SPECT-
Figure 1 Yearly Frequency of Abnormal and Ischemic SPECT-M
The frequency of abnormal and ischemic single-photon emission computed tomog
to 2009. A progressive decline was noted in both frequencies.MPI studies, ranging from 29.6% in 1991 to only 5.0% in
2009 (p  0.0001). The prevalence of moderately to
severely abnormal SPECT studies also declined progres-
sively, from 20.6% in 1991 to 4.6% in 2009 (p 0.0001), as
did the prevalence of transient ischemic dilation of the left
ventricle.
Table 2 shows the decline in the prevalence of abnormal
SPECT-MPI studies according to patients’ relevant clinical
parameters. There was a progressive decline in the preva-
lence of abnormal SPECT studies in all age groups; both
sexes; all ethnicities; both outpatients and inpatients; all
symptom, risk factor, and medication subgroups; and
among both patients referred for exercise and patients
referred for pharmacological stress. Similarly, the prevalence
of ischemic SPECT studies also declined significantly in
each of these clinical subgroups (p  0.001 for each clinical
parameter; data not shown).
When the 1,000 randomly selected patients in the first
epoch were compared with the propensity matched subsets
from the subsequent 3 epochs, there were no significant
differences between the patients in each epoch for the
matching variables: age (p  0.93); sex (p  0.66); chest
ain symptoms (p  0.65); hypertension (p  0.49);
ypercholesterolemia (p  0.83); smoking (p  0.32);
iabetes (p  0.52); family history of premature CAD (p 
.11); body mass index (p  0.54); and type of stress test (p 
.79). Within this propensity-matched cohort, the temporal
ecline in the frequency of abnormal SPECT studies persisted
ver our 4 epochs: 31.5%, 14.8%, 12.5%, and 10.7%, respectively
Table 3).
Figure 2 shows the prevalence of observing an abnormal
PECT study for the most current temporal subgroup of
atients (2006 to 2009) among exercise versus pharmaco-
ogical patients, after excluding the 247 exercise patients
5.9%) who did not achieve 85% of maximal predicted
eart rate. Among exercising patients without typical an-
SPECT) myocardial perfusion imaging (MPI) studies are shown by year from 1991PI
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March 12, 2013:1054–65 Temporal Trends in Ischemiagina, the prevalence of an abnormal SPECT-MPI study
was only 2.9%.
Temporal predictors of abnormal and ischemic SPECT-
MPI studies. Table 4 compares the adjusted odds ratios for
observing an abnormal SPECT-MPI study during each
temporal period according to our study parameters. In-
creased age, male sex, inpatient status, typical angina,
dyspnea, hypertension, smoking, diabetes, higher body mass
index, an abnormal rest electrocardiogram, the use of
cardioprotective medication, and the performance of phar-
macological stress testing were consistent predictors of an
abnormal SPECT-MPI study during each of our 4 tempo-
ral periods.
Discussion
Our study documents a marked and progressive decline in
the frequency of abnormal and ischemic SPECT-MPI
studies among diagnostic patients over the last 2 decades.
Whereas the frequency of abnormal studies was 40.9% in
1991, by 2009, the frequency of abnormal SPECT-MPI
studies among our diagnostic patients decreased to only
8.7% and the frequency of myocardial ischemia decreased
from 29.6% to only 5.0%. We also observed a substantive
and progressive decrease in the frequency of moderate to
severely abnormal and ischemic SPECT-MPI studies. No-
tably, the declining frequency of abnormal and ischemic
SPECT-MPI studies was broad-based, occurring among
both younger and older patients, in men and women, within
all ethnicities, among inpatients and outpatients, in both
asymptomatic and symptomatic patients, within each CAD
risk factor subgroup, and among both patients undergoing
exercise or pharmacological SPECT-MPI. Of further note,
the incidence of positive MPI-SPECT studies continued to
decrease in our most recent study group even following the
release of American College of Cardiology/American Heart
Association guidelines in 2003 (19) and appropriate use
criteria in 2005 (20), which were introduced to reduce
inappropriate use of MPI-SPECT as an initial test in
low-risk and intermediate-risk subjects.
Temporal trends in baseline clinical parameters. The
declining frequency of abnormal SPECT-MPI was accom-
panied by a progressive change in a variety of baseline
clinical parameters. These included a temporal decline in
patient age; a mild increase in the percentage of women
tested; less typical angina patients; a decline in smoking; and
increasing weight, obesity, and diabetes. In addition, the
frequency of hypertension rose during each successive tem-
poral period, but baseline systolic and diastolic blood pres-
sure levels were lower in the 2006 to 2009 epoch, probably
due to the progressively greater use of antihypertensive
medications in our patient population. Lipid-lowering
medications and aspirin use also increased progressively.
Due to the changing pattern of risk factors over time, we
also performed a propensity analysis that resulted in
subgroups of similar age, sex, symptom class, and risk afactor profiles across our 4 epochs. Our observed tempo-
ral decline in the frequency of SPECT-MPI abnormality
was maintained within these propensity-matched
subgroups.
Predictors of SPECT-MPI abnormality and ischemia.
Despite the temporal decline in SPECT-MPI abnormality
and changing characteristics of our referred patient popula-
tion, the clinical predictors of SPECT-MPI abnormality
and ischemia remained highly consistent over time. Predic-
tors included increasing age, male sex, inpatient status,
typical angina, dyspnea, hypertension, smoking, diabetes,
increasing body mass index, pharmacological stress, and an
abnormal resting electrocardiogram. The prevalence of ab-
normality was also elevated among those patients taking
cardioprotective medications compared with those who did,
probably reflecting higher risk among such patients.
Prior studies. Even though our current database began in
1991, we had previously studied patients who had under-
gone exercise thallium planar MPI studies in the late 1970s
and 1980s (21). At that time, the frequency of abnormal
xercise MPI studies was 50% among 1,689 diagnostic
atients, which was nearly twice the frequency noted for
xercise SPECT-MPI abnormality in the earliest temporal
eriod of our study (i.e., 27.5%), and other studies con-
ucted during that time also noted a similarly high fre-
uency of abnormal MPI studies (22). Thus, consideration
f this earlier literature suggests that the temporal decline in
tress MPI abnormality since the late 1970s may be even
reater than that documented in our study.
otential explanations. A number of mechanisms may
ccount for our findings. First, reduction in risk factors, as
bserved in our study, could have served to reduce ischemia
y retarding the progression of atherosclerosis and/or by
avorably influencing pathophysiological determinants of
yocardial ischemia, such as endothelial dysfunction (23).
n our referral population, there was a mixed pattern of
emporal CAD risk factor change. Favorable changes in-
luded progressive decline in smoking, family history of
remature CAD, and resting blood pressure measurements.
n addition, though not measured in our study, there have
lso been declining cholesterol levels (1) and transfat inges-
ion among Americans (24), and these trends may also have
een applicable in our patients as well. However, we noted
rogressive rise in obesity and diabetes. Of note, in an
nalysis that included similar change of CAD risk factor
hange, including rise in obesity and diabetes, Ford et al. (3)
till attributed 44% of an observable national decline in
ardiovascular deaths to risk factor reduction and similar
ndings have been noted by others (25).
Second, our data raise a question as to whether there has
een a concomitant trend toward less severe angiographic
isease in the presence of cardiac symptoms. Specifically, we
oted a progressive decline in the frequency of SPECT-
PI abnormality in each of our chest pain groups, including
atients with typical angina. The frequency of SPECT-MPI
bnormality was 51.6% among typical angina patients referred
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Temporal Trends in Ischemia March 12, 2013:1054–65for testing between 1991 and 1996, but it was only 22.6%
among patients referred for testing between 2006 and 2009. In
support of this notion, recent invasive and noninvasive angio-
graphic studies indicate a lower contemporary prevalence of
angiographically significant CAD among typical angina pa-
tients as compared to previous studies (26–28).
Third, progressively greater use of cardiac medications
may have contributed to our findings. The increasing use of
Temporal Prevalence of Abnormal SPECT AccorTable 2 Temporal Prevalence of Abnormal S
Clinical Parameters
1991–1995
(n  6,335)
1996–2
(n  10
Age group, yrs
55 270 (17.6) 188 (
55–64 407 (28.9) 295 (
65 1,369 (40.4) 1,183 (
Sex
Female 751 (26.4) 555 (
Male 1,295 (37.1) 1,111 (
Ethnicity
Caucasian 1,679 (33.5) 1,298 (
African American 160 (31.6) 136 (
Asian/Pacific Islander 61 (28.6) 51 (
Hispanic/Latino 37 (30.1) 52 (
Patient status
Outpatient 1,400 (30.7) 1,124 (
Inpatient 646 (36.4) 542 (
Emergency department — —
Symptom class
Asymptomatic 608 (30.0) 367 (
Nonanginal chest pain 385 (23.5) 199 (
Atypical angina 515 (32.8) 479 (
Typical angina 414 (51.6) 373 (
Dyspnea only 124 (42.5) 248 (
Coronary risk factors
Family history
No 1,621 (33.1) 1,321 (
Yes 425 (29.7) 345 (
Hypertension
No 933 (27.6) 634 (
Yes 1,113 (37.7) 1,032 (
High cholesterol
No 1,199 (31.9) 897 (
Yes 847 (33.0) 769 (
Smoking
No 1,684 (31.9) 1,455 (
Yes 362 (34.3) 211 (
Diabetes
No 1,644 (30.1) 1,362 (
Yes 402 (46.2) 304 (
Body mass index, kg/m2
Normal 25 824 (30.8) 540 (
Overweight, 25–29.9 819 (33.0) 712 (
Obese, 30 377 (33.8) 410 (
Rest electrocardiogram
Normal 492 (22.2) 426 (
Abnormal 1,554 (37.8) 1,240 (statins may be of particular relevance because their pleio-tropic effects have been associated with ischemia reduction,
including reversal of SPECT-MPI perfusion defects
(29,30). However, the more aggressive use of statins does
not account for the relatively comparable decline in
SPECT-MPI abnormality between both patients taking
and patients not taking statins in our cohort.
Fourth, temporal changes in patient referral patterns may
have been influential. Just as the mean age of our patient
o Clinical ParametersAccording to Clinical Parameters
2001–2005
(n  14,089)
2006–2009
(n  8,827) p Values (Trend)
317 (6.4) 160 (4.7) 0.001 (0.0001)
368 (10.4) 211 (8.8) 0.001 (0.0001)
953 (17.0) 458 (15.2) 0.001 (0.0001)
581 (8.5) 282 (6.6) 0.001 (0.0001)
1,057 (14.6) 547 (12.1) 0.001 (0.0001)
1,128 (12.1) 513 (9.7) 0.001 (0.0001)
271 (12.5) 184 (10.4) 0.001 (0.0001)
63 (10.0) 33 (5.9) 0.001 (0.0001)
122 (11.5) 81 (8.3) 0.001 (0.0001)
878 (9.9) 393 (7.8) 0.001 (0.0001)
742 (15.7) 410 (13.7) 0.001 (0.0001)
18 (3.5) 26 (3.3) 0.93 (0.88)
358 (11.2) 210 (10.5) 0.001 (0.0001)
180 (11.9) 57 (12.2) 0.001 (0.0001)
730 (9.4) 374 (7.1) 0.001 (0.0001)
153 (32.1) 37 (22.6) 0.001 (0.0001)
217 (18.7) 151 (16.2) 0.001 (0.0001)
1,490 (12.0) 757 (10.0) 0.001 (0.0001)
148 (9.0) 72 (5.9) 0.001 (0.0001)
471 (8.1) 164 (5.0%) 0.001 (0.0001)
1,167 (14.2) 665 (12.0%) 0.001 (0.0001)
814 (10.6) 367 (8.3) 0.001 (0.0001)
824 (12.9) 462 (10.5) 0.001 (0.0001)
1,507 (11.5) 747 (9.3) 0.001 (0.0001)
131 (12.8) 82 (11.0) 0.001 (0.0001)
1,186 (10.0) 546 (7.7) 0.001 (0.0001)
452 (20.6) 283 (16.5) 0.001 (0.0001)
499 (10.4) 237 (8.2) 0.001 (0.0001)
616 (11.7) 291 (9.3) 0.001 (0.0001)
520 (13.0) 299 (10.7) 0.001 (0.0001)
504 (6.5) 265 (5.4) 0.001 (0.0001)
1,134 (17.9) 564 (14.6) 0.001 (0.0001)
Continued on the next pageding tPECT
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March 12, 2013:1054–65 Temporal Trends in Ischemiareferring patients with milder intensity and/or duration of
symptoms for cardiac stress testing. Also, although it could
not be assessed in our study, it is possible that physicians
now have a lower threshold for referring patients with more
severe anginal symptoms directly to cardiac catheterization.
The increasing use of pharmacological stress testing. There
was a progressively greater utilization of pharmacological
testing over time. Notably, neither age nor the increasing
weight of our patient population seemed to explain this
trend because pharmacological testing increased in every age
group and weight class. Potential explanations could include
a lower threshold for converting poorly exercising patients
to pharmacological stress, a greater tendency to use phar-
macological stress due to convenience, and increasingly
sedentary behavior or deconditioning among referred pa-
tients. Prior data in patients with normal SPECT-MPI have
emonstrated higher mortality rates among those undergoing
harmacological testing versus exercise testing, even when
atched on the basis of age, sex, and other clinical factors and
xcluding patients with pre-existing cardiac morbidities (31).
In addition, our present data also indicate that pharmacological
stress is associated with a greater likelihood of observing
abnormal and ischemic SPECT-MPI studies.
Combined, these data indicate that patients undergoing
pharmacological stress testing are at higher a priori risk and
thus deserving of a lower threshold for testing than are
patients who can exercise. Thus, prospective study is indi-
cated to ascertain the causes for increasing use of pharma-
cological stress testing, to investigate why such patients are
at increased ischemia risk, and to better ascertain the reasons
for increased prognostic risk among even pharmacological
patients without inducible myocardial ischemia (31).
tudy limitations and strengths. Although the study sam-
le in the present study was very large, 1 principle limitation
s that the data reported herein constitute the experience
rom a single medical center, which may have been signif-
ContinuedTable 2 Continued
Clinical Parameters
1991–1995
(n  6,335)
1996–2
(n  10
Medication use
Statins
No — 259 (1
Yes — 68 (1
Blood pressure medications
No — 224 (1
Yes — 103 (1
Aspirin
No — 290 (1
Yes — 37 (1
Testing modality
Exercise 1,223 (27.5) 681 (1
Pharmacological stress 823 (43.8) 985 (2
Values are n (%). —  data were not available.
SPECT  single-photon emission computed tomography.cantly affected by referral bias. Thus, there is a need to conduct similar temporal analyses in other stress test pop-
lations. Because our cohort was generally Caucasian,
hough it had decreased to 60% by the 2006 to 2009 period,
aution should be applied in extrapolating our findings to
ther ethnic groups. We did not collect information regard-
ng the chronicity or intensity of CAD risk factors, the
everity of chest pain symptoms, or the distribution of
hysician specialties referring patients to our laboratory.
he latter would be of potential interest for assessing
hether changing frequencies in the distribution of referrals
y cardiologists versus more general physicians helped
ontribute to our findings. During the course of our study,
arious technical innovations were introduced regarding our
erformance of SPECT-MPI, including the introduction of
outine gated imaging for assessing regional wall motion
nd the combined use of both prone and supine imaging
ince the mid-1990s. However, these technical improve-
ents, per se, are not likely to be a major cause for our
ndings because the frequency of abnormal SPECT-MPI
tudies declined continuously, both before and after these
echnical innovations took place. Concomitant quantitative
nalysis of our visually assessed scintigrams would have been
f further interest in this regard, but could not be performed
ue to a lack of imaging storage of our early studies.
Our study also has considerable strengths, including our
arge consecutive sample of stress test patients, our consis-
ent collection of the same baseline clinical data and scheme
or interpreting stress-rest MPI studies, and generally the
ame interpreters for SPECT-MPI throughout the tempo-
al span of our study.
linical implications. Two broad implications emanate
rom our findings. First, the declining frequency and sever-
ty of myocardial ischemia that was noted in our study may
e reflecting a broader temporal change toward milder
linical presentations of CAD. Indeed, not only has the
revalence of cardiac death and myocardial infarction de-
2001–2005
(n  14,089)
2006–2009
(n  8,827) p Values (Trend)
1,116 (10.6) 507 (8.3) 0.001 (0.0001)
522 (14.7) 322 (11.8) 0.003 (0.002)
691 (9.1) 234 (5.7) 0.001 (0.0001)
947 (14.7) 595 (12.7) 0.003 (0.0006)
1,145 (10.8) 516 (8.3) 0.001 (0.0001)
493 (14.1) 313 (12.0) 0.009 (0.003)
499 (7.0) 155 (3.7) 0.001 (0.0001)
1,139 (16.5) 674 (14.5) 0.001 (0.0001)000
,264)
2.4)
4.8)
1.7)
6.3)
2.4)
7.9)
1.3)
3.2)lined in the United States (1–3,5), but so too has the
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Temporal Trends in Ischemia March 12, 2013:1054–65severity of myocardial infarction (4). At the same time,
however, the overall prevalence of CAD remains high in
society, even among young individuals (32,33). Notably, we
performed concomitant coronary artery calcium (CAC)
scans in a sample of 1,195 of the patients who underwent
exercise SPECT-MPI in our laboratory (34). Among the
1,119 patients with normal exercise SPECT-MPI studies,
78% had evidence of atherosclerosis as detected by CAC
Temporal Prevalence of Abnormal SPECT Accorto Clinical Paramet rs in Propensity-MatchedTable 3 Temporal Prevalence of Abnormalto Clinical Parameters in Propens
Clinical Parameters
1991–1995
(n  1,000)
1996–2000
(n  1,000
Age group
Mean age, yrs 64.2 12.6 64.0 13.
55 32 (13.3) 12 (4.7)
55–64 64 (28.0) 32 (13.3)
65 219 (41.3) 104 (20.6)
Sex
Female 118 (25.9) 47 (10.0)
Male 197 (36.2) 101 (19.1)
Ethnicity
Caucasian 250 (32.1) 112 (15.2)
African American 34 (40.0) 8 (10.3)
Asian/Pacific Islander 11 (26.2) 5 (13.9)
Hispanic/Latino 3 (15.0) 4 (11.8)
Symptom class
Asymptomatic 83 (27.8) 28 (9.7)
Nonanginal chest pain 69 (24.4) 32 (11.1)
Atypical angina 66 (28.0) 30 (13.0)
Typical angina 75 (56.0) 43 (30.3)
Dyspnea only 22 (45.8) 15 (30.6)
Coronary risk factors
Family history
No 235 (31.9) 103 (13.9)
Yes 80 (30.3) 45 (17.2)
Hypertension
No 141 (27.1) 60 (11.1)
Yes 174 (36.3) 88 (19.2)
High cholesterol
No 196 (33.4) 77 (13.3)
Yes 119 (28.8) 71 (16.8)
Smoking
No 261 (31.5) 121 (14.7)
Yes 54 (31.4) 27 (15.5)
Diabetes
No 256 (29.5) 110 (12.5)
Yes 59 (45.0) 38 (31.4)
Mean weight 165.0 35.8 165.6 37.
Mean body mass index 26.2 4.6 26.1 4.9
Rest electrocardiogram
Normal 77 (21.7) 37 (7.6)
Abnormal 238 (36.9) 111 (21.6)
Testing modality
Exercise 189 (27.2) 76 (10.9)
Pharmacological 126 (41.5) 72 (23.6)
Values are mean  SD or n (%).
SPECT  single-photon emission computed tomography.scanning and 31% had CAC scores 400. Similar resultshave been noted by Chang et al. (35). Thus, despite the
current decline in the frequency of inducible myocardial
ischemia, overall plaque burden remains quite high in stress
testing cohorts.
Second, the declining frequency of inducible myocardial
ischemia, particularly among exercising patients without
typical angina, suggests a need to refine the future diagnos-
tic workup of patients with suspected CAD. Interestingly in
ntsCT According
atched Patients
001–2005
n  1,000)
2006–2009
(n  1,000) p Values (Trend)
4.2 13.2 64.4 13.4 0.93 (1.00)
13 (5.3) 13 (5.5) 0.001 (0.002)
25 (9.2) 25 (9.3) 0.001 (0.0001)
87 (18.1) 69 (13.9) 0.001 (0.0001)
35 (7.9) 28 (6.1) 0.001 (0.0001)
90 (16.2) 79 (14.5) 0.001 (0.0001)
94 (12.8) 78 (11.3) 0.001 (0.0001)
16 (15.4) 16 (10.6) 0.001 (0.0001)
6 (16.2) 4 (6.6) 0.05 (0.01)
8 (13.8) 6 (8.1) 0.71 (0.36)
39 (13.2) 27 (8.4) 0.001 (0.0001)
26 (9.2) 29 (10.9) 0.001 (0.0001)
18 (7.9) 16 (6.8) 0.001 (0.0001)
32 (23.7) 25 (22.1) 0.001 (0.0001)
10 (17.2) 10 (15.6) 0.001 (0.0001)
108 (15.0) 92 (12.0) 0.001 (0.0001)
17 (6.1) 15 (6.5) 0.001 (0.0001)
50 (9.6) 41 (8.1) 0.001 (0.0001)
75 (15.6) 66 (13.4) 0.001 (0.0001)
63 (10.7) 59 (10.3) 0.001 (0.0001)
62 (15.2) 48 (11.2) 0.001 (0.0001)
110 (13.1) 95 (11.1) 0.001 (0.0001)
15 (9.4) 12 (8.2) 0.001 (0.0001)
97 (11.0) 79 (9.1) 0.001 (0.0001)
28 (24.1) 28 (20.6) 0.001 (0.0001)
6.4 38.4 166.3 38.4 0.99 (0.76)
6.1 5.1 26.1 5.1 0.54 (0.19)
42 (7.6) 45 (7.9) 0.001 (0.0001)
83 (18.4) 62 (14.5) 0.001 (0.0001)
70 (10.1) 46 (6.9) 0.001 (0.0001)
55 (17.7) 61 (18.3) 0.001 (0.0001)dingPatieSPE
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)
2
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2this regard, repeated study has now demonstrated a thresh-
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March 12, 2013:1054–65 Temporal Trends in IschemiaTemporal Risk-Adjusted OR for Having an Abnormal SPECT StudyTable 4 Temporal Risk-Adjusted OR for Having an Abnormal SPECT Study
Variables All Patients 1991–1995 1996–2000 2001–2005 2006–2009
Age per 5 yrs 1.25 (1.2–1.3),0.001 1.24 (1.2–1.3),0.001 1.24 (1.2–1.3),0.001 1.20 (1.17–1.23),0.001 1.21 (1.2–1.3),0.001
Sex
Female 1.00 1.00 1.00 1.00 1.00
Male 2.47 (2.3–2.6),0.001 2.53 (2.2–2.9),0.001 2.89 (2.5–3.3),0.001 2.69 (2.4–3.0),0.001 2.62 (2.2–3.1),0.001
BMI per 5 kg/m2 1.06 (1.04–1.1),0.001 1.10 (1.03–1.2), 0.004 1.08 (1.02–1.1), 0.009 1.09 (1.05–1.1),0.001 1.10 (1.05–1.2),0.001
Ethnicity
Caucasian 1.00 1.00 1.00 1.00 1.00
African American 0.91 (0.8–1.0), 0.06 0.99 (0.8–1.2), 0.95 0.83 (0.7–1.02), 0.08 1.12 (1.0–1.3), 0.17 1.13 (0.9–1.4), 0.21
Asian/Pacific Islander 0.79 (0.7–0.9), 0.004 0.95 (0.7–1.3), 0.75 1.03 (0.7–1.4), 0.87 0.89 (0.7–1.2), 0.44 0.66 (0.5–0.97), 0.04
Hispanic/Latino 0.77 (0.7–0.9),0.001 1.00 (0.7–1.5), 1.00 0.81 (0.6–1.1), 0.21 1.01 (0.8–1.3), 0.91 0.90 (0.7–1.2), 0.45
Patient status
Outpatient 1.00 1.00 1.00 1.00 1.00
Inpatient 1.23 (1.1–1.3),0.001 1.12 (1.0–1.3), 0.11 1.01 (0.9–1.2), 0.93 1.42 (1.3–1.6),0.001 1.58 (1.3–1.9),0.001
Emergency department — — — 0.70 (0.4–1.1), 0.16 1.20 (0.8–1.9), 0.41
Patient symptoms
Asymptomatic patient 1.00 1.00 1.00 1.00 1.00
Nonanginal chest pain 1.01 (0.9–1.1), 0.81 0.81 (0.7–0.9), 0.009 1.02 (0.8–1.2), 0.81 0.88 (0.7–1.1), 0.21 0.82 (0.6–1.1), 0.25
Atypical angina 0.86 (0.8–0.9),0.001 1.22 (1.05–1.4), 0.01 1.23 (1.05–1.4), 0.01 0.96 (0.8–1.1), 0.59 0.81 (0.7–0.99), 0.04
Typical angina 3.68 (3.3–4.1),0.001 2.48 (2.1–3.0),0.001 3.57 (3.0–4.3),0.001 4.95 (3.9–6.3),0.001 3.93 (2.6–6.0),0.001
Dyspnea 1.22 (1.1–1.4),0.001 1.22 (0.9–1.6), 0.15 1.79 (1.5–2.2),0.001 1.43 (1.2–1.7),0.001 1.32 (1.03–1.7), 0.03
CAD risk factors
Family history
No 1.00 1.00 1.00 1.00 1.00
Yes 1.15 (1.1–1.2), 0.001 1.00 (0.9–1.1), 0.98 1.10 (1.0–1.3), 0.18 0.96 (0.8–1.2), 0.67 0.89 (0.7–1.2), 0.39
Hypertension
No 1.00 1.00 1.00 1.00 1.00
Yes 1.13 (1.1–1.2),0.001 1.27 (1.1–1.4),0.001 1.27 (1.1–1.4),0.001 1.16 (1.02–1.3), 0.02 1.35 (1.1–1.6), 0.003
History of high cholesterol
No 1.00 1.00 1.00 1.00 1.00
Yes 1.07 (1.005–1.1), 0.04 1.16 (1.03–1.3), 0.01 1.22 (1.1–1.4), 0.001 1.31 (1.2–1.5),0.001 1.09 (0.9–1.3), 0.32
Smoking
No 1.00 1.00 1.00 1.00 1.00
Yes 1.54 (1.4–1.7),0.001 1.27 (1.1–1.5), 0.003 1.34 (1.1–1.6), 0.001 1.23 (1.0–1.5), 0.05 1.32 (1.01–1.7), 0.04
History of diabetes
No 1.00 1.00 1.00 1.00 1.00
Yes 1.74 (1.6–1.9),0.001 1.57 (1.3–1.8),0.001 1.87 (1.6–2.2),0.001 1.75 (1.5–2.0),0.001 1.66 (1.4–2.0),0.001
Heart rate per 5 beats/min 1.06 (1.05–1.08),0.001 1.07 (1.04–1.09),0.001 1.05 (1.03–1.07),0.001 1.06 (1.04–1.09),0.001 1.06 (1.03–1.09),0.001
SBP per 5 mm Hg 1.03 (1.02–1.035),0.001 1.01 (1.0–1.03), 0.08 1.03 (1.02–1.04),0.001 1.003 (1.0–1.02), 0.71 1.00 (0.98–1.02), 0.98
DBP per 5 mm Hg 1.07 (1.05–1.08),0.001 0.99 (0.96–1.01), 0.35 1.04 (1.01–1.07), 0.002 1.04 (1.02–1.07), 0.001 1.01 (0.97–1.05), 0.62
Rest ECG
Normal 1.00 1.00 1.00 1.00 1.00
Abnormal 2.30 (2.2–2.5),0.001 1.56 (1.4–1.8),0.001 2.10 (1.8–2.4),0.001 2.37 (2.1–2.7),0.001 1.90 (1.6–2.2),0.001
Stress mode
Exercise 1.00 1.00 1.00 1.00 1.00
Pharmacological stress 1.43 (1.3–1.5),0.001 1.56 (1.4–1.8),0.001 1.83 (1.6–2.1),0.001 1.93 (1.7–2.2),0.001 2.63 (2.1–3.2),0.001
Medication use
No lipid medications — — — 1.00 1.00
Use of lipid medications — — — 1.16 (1.0–1.4), 0.07 1.02 (0.8–1.3), 0.88
No HBP medications — — — 1.00 1.00
Use of HBP medications — — — 1.01 (0.9–1.2), 0.91 1.29 (0.99–1.7), 0.06
No aspirin — — — 1.00 1.00
Use of aspirin — — — 1.02 (0.9–1.1), 0.80 1.09 (0.9–1.3), 0.29
Values are OR or OR (95% CI), p values.— data were unavailable. Adjusted for age, sex, bodymass index, chest pain symptom, ethnicity, inpatient versus outpatient status, stress test mode, family history,
hypertension, high cholesterol, diabetes, and smoking. Tests for interactions between every predictor and epoch (second, third, fourth versus first) in the overall cohort revealed interactions between epoch
and the following variables: age, ethnicity, inpatient versus outpatient status, chest pain symptom, family history, hypertension, hyperlipidemia, smoking, diabetes, heart rate, SBP, DBP, abnormal rest ECG,
lipid-lowering medications, blood pressure medications, aspirin usage, and pharmacological test type.
ECG  electrocardiogram; DBP  diastolic blood pressure; HBP  high blood pressure; OR  odds ratio(s); SBP  systolic blood pressure; other abbreviations as in Table 1.
s
t
s
s
c
p
B
a
p
m
e
n
c
s
d
i
a
w
p
1064 Rozanski et al. JACC Vol. 61, No. 10, 2013
Temporal Trends in Ischemia March 12, 2013:1054–65old relationship between CAC scores and the likelihood of
inducible myocardial ischemia (36–39). Accordingly, CAC
canning has the potential to serve as a useful means for
riaging patients toward cardiac stress testing when CAC
cores are high and away from stress testing when CAC
cores are low. Among those patients who are exercise
andidates, assessment of patients’ functional capacity may
rovide additional triaging information in light of data from
ourque et al. (40,41) that demonstrate that achievement of
high workload during treadmill exercise electrocardiogra-
hy is associated with a very low frequency of inducible
yocardial ischemia by SPECT-MPI imaging and cardiac
vents among such patients. Conceivably then, CAC scan-
ing, with or without treadmill exercise electrocardiography,
ould serve as potentially low-cost alternative to more expen-
ive imaging tests for the initial workup of relatively lower-risk
iagnostic patients. Thus, prospective clinical trials now appear
ndicated to assess whether utilization of such lower-cost
lternatives provides comparable or improved diagnostic
orkup and subsequent management of patients with sus-
ected CAD while incurring lower overall healthcare costs.
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